Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Biosimilar | 2 |
Prophylactic vaccine | 2 |
Genetically engineered subunit vaccine | 1 |
Colony-stimulating factors | 1 |
Enzyme | 1 |
Top 5 Target | Count |
---|---|
EPO receptor(Erythropoietin receptor) | 1 |
PLG(Plasminogen) | 1 |
Target- |
Mechanism Immunostimulants |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Mar 2014 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Jan 1997 |
Target |
Mechanism CSF-3R agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Jan 2019 |
Sponsor / Collaborator |
Start Date28 Dec 2018 |
Sponsor / Collaborator |
Start Date13 May 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Streptokinase biosimilar(Sanofi Healthcare India Pvt Ltd.) ( PLG ) | Myocardial Infarction More | Approved |
DTwP-HebB-Hib vaccine(Sanofi) | Whooping Cough More | Approved |
Hepatitis B vaccine recombinant(Sanofi Healthcare India Pvt Ltd.) | Hepatitis B More | Approved |
Erythropoietin biosimilar(Sanofi Healthcare India Pvt Ltd.) ( EPO receptor ) | Anemia More | Approved |
Recombinant Human Granulocyte Colony Stimulating Factor(Shantha Biotechnics) ( CSF-3R ) | Neutropenia More | Pending |